http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007032555-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_32f57a53515b98afbb284cb39a2f17f7 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B2200-05 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07B59-001 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C217-48 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C217-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-138 |
| filingDate | 2006-06-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ca0dcfc0e6ca1de359c70eb370641b4c |
| publicationDate | 2007-02-08-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | US-2007032555-A1 |
| titleOfInvention | Novel aryloxyphenyl-propanamines |
| abstract | The present invention relates to a non-radioactive, heavy-atom isotopologue of Compound 1 containing one or more deuterium in place of a hydrogen covalently bound to carbon. The Compound 1 isotopologues of the invention are inhibitors of norepinephrine uptake and possess unique biopharmaceutical and pharmacokinetic properties compared to the corresponding non-isotope containing compounds. They may also be used to accurately determine the concentration of Compound 1 in biological fluids. The invention further provides compositions comprising these heavy-atom Compound 1 isotopologue and methods of treating diseases and conditions linked to reduced neurotransmission of norepinephrine. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2007155820-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2010063141-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-9061060-B2 |
| priorityDate | 2005-07-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 1293.